Developer docs
API playgroundTry for free, no card

Search company profiles

MEDTOX Diagnostics

Full company profile

uuid000k7rh

Namestring
MEDTOX Diagnostics
Legal namestring
MEDTOX Diagnostics, Inc.
Company typeenum
Private
Founded yearint
1987
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBurlington, United States
HQ citystring
Burlington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug testing devices, immunoassay urine screening, point of care diagnostics, workplace drug screening, fentanyl urine test
Industry2 codes
PRIMARYHLAHAOAG
Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAGADAC
Release Testing & Batch Certification (QC)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Point-of-Care Drug Testing Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Testing Devices and Consumables
TypeOne Time License
Description

MEDTOX generates revenue through the sale of drug testing devices (cassettes, cups) and related consumables. The company sells directly to hospitals, workplaces, criminal justice facilities, and clinical trial organizations. Products are available via sales representatives and direct reorder.

medtoxdiagnostics.com
2MEDTOXScan Reader Hardware and Licensing
TypeHardware Sales
Description

Sale of MEDTOXScan automated readers that read PROFILE-V cassette test results, combined with ongoing support services for laboratory information system integration and technical support.

medtoxdiagnostics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1MEDTOXScan
Description

Automated drug testing reader that provides screening results within 10 minutes, tests for up to 12 drugs of abuse.

medtoxdiagnostics.com
+3 more records
Core offering1 text field

MEDTOX Diagnostics manufactures and sells FDA 510(k)-cleared rapid drug testing devices, including single-step immunoassay cassettes and cups that deliver qualitative urine drug screening results within minutes. The portfolio includes the MEDTOXScan automated reader system, multi-panel cassettes (PROFILE and VERDICT lines), EZ-SCREEN cups with on-board adulteration strips, and the Labcorp Fentanyl Test, all produced at its Burlington, North Carolina facility under ISO 13485:2016 quality certification.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Screening results delivered in 10 minutes
+4 more records
Product overview1 text field

MEDTOX Diagnostics is a portfolio of drug testing devices and solutions, transitioning to Labcorp Point of Care in 2026. The company offers rapid, one-step immunoassay urine drug screening devices available in cassette and cup form, along with the MEDTOXScan automated reader system. Cassette products include PROFILE-II, PROFILE-IIA, PROFILE-II ER, VERDICT-II, and PROFILE-V (for MEDTOXScan), testing for 7-12 drugs of abuse. Cup products include EZ-SCREEN (HI) and EZ-SCREEN (LO), testing for up to 11 drugs. The MEDTOXScan reader automates cassette testing with barcode scanning, digital results, and laboratory information system connectivity. All devices are FDA 510(k)-cleared, manufactured in Burlington, North Carolina, with ISO 13485:2016 quality management system certification.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

During 2026, the trade name for MEDTOX Diagnostics products will transition to Labcorp Point of Care. MEDTOX Diagnostics operates as part of Labcorp's point-of-care diagnostics portfolio, with their fentanyl test product line being marketed under the Labcorp Point of Care brand. Labcorp has launched the FDA-cleared fentanyl test manufactured by MEDTOX under the Labcorp branding.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Abbott's toxicology business (built on the Alere acquisition) sells rapid point-of-care drugs-of-abuse immunoassay devices and readers, directly competing with MEDTOX cassettes and cups across workplace, criminal justice, and clinical settings.

TypeBroad incumbent
Description

Roche offers broad clinical chemistry, immunoassay, and toxicology menus through centralized lab analyzers (cobas) used by hospital laboratories — overlapping with MEDTOX's drug-screening applications, especially in clinical/hospital use cases.

TypeBroad incumbent
Description

Siemens provides clinical chemistry and immunoassay analyzers (Atellica, ADVIA Centaur) widely used in hospital labs for drug screening confirmation, competing with MEDTOX's hospital-side toxicology workflow at the lab-confirmation stage.

TypeDirect peer
Description

Quest operates one of the largest US reference laboratory toxicology businesses, providing lab-based drug testing services and increasingly offering rapid point-of-care options — competing directly with MEDTOX for workplace, criminal justice, and clinical customers.

TypeDirect peer
Description

Psychemedics is a specialty drug-testing laboratory focused on hair follicle testing for drugs of abuse, serving employers, courts, and schools — competing with MEDTOX in the same end-markets via a different specimen matrix.

TypeEmerging player
Description

OraSure develops oral fluid collection devices (Intercept) used in workplace and criminal justice drug testing, representing a modality alternative to MEDTOX's urine-based immunoassays.

TypeDirect peer
Description

CRL provides lab-based drugs-of-abuse testing services to employers, government, and clinical trial sponsors, competing with MEDTOX's confirmatory lab workflow following on-site screening.

TypeDirect peer
Description

Premier Biotech manufactures rapid urine-based drugs-of-abuse test cups and cassettes (similar SKU range to MEDTOX) and sells into workplace, clinical, and law enforcement channels — a closely comparable direct competitor in the rapid toxicology device category.

TypeEmerging player
Description

Confirm Biosciences offers a portfolio of rapid urine drug test cups and saliva-based oral fluid drug testing kits, overlapping with MEDTOX's product line especially in workplace and at-home testing channels.

TypeBroad incumbent
Description

Labcorp is MEDTOX's parent company and a dominant reference lab for drugs-of-abuse confirmation testing — providing both distribution synergy and competitive overlap as Labcorp expands its Point of Care portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MEDTOX Diagnostics

Point-of-Care Drug Testing Devicesmedtoxdiagnostics.com

MEDTOX Diagnostics firmographics

Firmographics
Name
MEDTOX Diagnostics
Legal name
MEDTOX Diagnostics, Inc.
Website
https://medtoxdiagnostics.com
Company type
Private
Founded year
1987
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

MEDTOX Diagnostics industry classification

Industry
Product category
Point-of-Care Drug Testing Devices
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAOAG
Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAGADAC
Release Testing & Batch Certification (QC)

Keywords

  • Drug testing devices
  • Immunoassay urine screening
  • Point of care diagnostics
  • Workplace drug screening
  • Fentanyl urine test

Where MEDTOX Diagnostics is headquartered

Location

Headquarters

HQ city
Burlington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

MEDTOX Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

  1. Drug Testing Devices and Consumables: MEDTOX generates revenue through the sale of drug testing devices (cassettes, cups) and related consumables. The company sells directly to hospitals, workplaces, criminal justice facilities, and clinical trial organizations. Products are available via sales representatives and direct reorder.
  2. MEDTOXScan Reader Hardware and Licensing: Sale of MEDTOXScan automated readers that read PROFILE-V cassette test results, combined with ongoing support services for laboratory information system integration and technical support.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

MEDTOX Diagnostics product offering

Product offering

Core offering

MEDTOX Diagnostics manufactures and sells FDA 510(k)-cleared rapid drug testing devices, including single-step immunoassay cassettes and cups that deliver qualitative urine drug screening results within minutes. The portfolio includes the MEDTOXScan automated reader system, multi-panel cassettes (PROFILE and VERDICT lines), EZ-SCREEN cups with on-board adulteration strips, and the Labcorp Fentanyl Test, all produced at its Burlington, North Carolina facility under ISO 13485:2016 quality certification.

Product overview

MEDTOX Diagnostics is a portfolio of drug testing devices and solutions, transitioning to Labcorp Point of Care in 2026. The company offers rapid, one-step immunoassay urine drug screening devices available in cassette and cup form, along with the MEDTOXScan automated reader system. Cassette products include PROFILE-II, PROFILE-IIA, PROFILE-II ER, VERDICT-II, and PROFILE-V (for MEDTOXScan), testing for 7-12 drugs of abuse. Cup products include EZ-SCREEN (HI) and EZ-SCREEN (LO), testing for up to 11 drugs. The MEDTOXScan reader automates cassette testing with barcode scanning, digital results, and laboratory information system connectivity. All devices are FDA 510(k)-cleared, manufactured in Burlington, North Carolina, with ISO 13485:2016 quality management system certification.

Differentiator

Problem solved

Functional benefit

Brands

  • MEDTOXScan: Automated drug testing reader that provides screening results within 10 minutes, tests for up to 12 drugs of abuse.
  • PROFILE
  • VERDICT
  • EZ-SCREEN

Quantifiable outcome

  • Screening results delivered in 10 minutes
  • +4 more outcomes

Companies that use MEDTOX Diagnostics

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

MEDTOX Diagnostics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

MEDTOX Diagnostics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • LabcorpcoreStrategic or Co-development Partner · 1 January 2026During 2026, the trade name for MEDTOX Diagnostics products will transition to Labcorp Point of Care. MEDTOX Diagnostics operates as part of Labcorp's point-of-care diagnostics portfolio, with their fentanyl test product line being marketed under the Labcorp Point of Care brand. Labcorp has launched the FDA-cleared fentanyl test manufactured by MEDTOX under the Labcorp branding.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

MEDTOX Diagnostics competitors and assessment

Company assessment

Direct peers

  • Abbott Toxicology (formerly Alere): Abbott's toxicology business (built on the Alere acquisition) sells rapid point-of-care drugs-of-abuse immunoassay devices and readers, directly competing with MEDTOX cassettes and cups across workplace, criminal justice, and clinical settings.
  • Quest Diagnostics: Quest operates one of the largest US reference laboratory toxicology businesses, providing lab-based drug testing services and increasingly offering rapid point-of-care options — competing directly with MEDTOX for workplace, criminal justice, and clinical customers.
  • Psychemedics Corporation: Psychemedics is a specialty drug-testing laboratory focused on hair follicle testing for drugs of abuse, serving employers, courts, and schools — competing with MEDTOX in the same end-markets via a different specimen matrix.
  • Clinical Reference Laboratory: CRL provides lab-based drugs-of-abuse testing services to employers, government, and clinical trial sponsors, competing with MEDTOX's confirmatory lab workflow following on-site screening.
  • Premier Biotech: Premier Biotech manufactures rapid urine-based drugs-of-abuse test cups and cassettes (similar SKU range to MEDTOX) and sells into workplace, clinical, and law enforcement channels — a closely comparable direct competitor in the rapid toxicology device category.

Broad incumbents

  • Roche Diagnostics: Roche offers broad clinical chemistry, immunoassay, and toxicology menus through centralized lab analyzers (cobas) used by hospital laboratories — overlapping with MEDTOX's drug-screening applications, especially in clinical/hospital use cases.
  • Siemens Healthineers: Siemens provides clinical chemistry and immunoassay analyzers (Atellica, ADVIA Centaur) widely used in hospital labs for drug screening confirmation, competing with MEDTOX's hospital-side toxicology workflow at the lab-confirmation stage.
  • Labcorp: Labcorp is MEDTOX's parent company and a dominant reference lab for drugs-of-abuse confirmation testing — providing both distribution synergy and competitive overlap as Labcorp expands its Point of Care portfolio.

Emerging players

  • OraSure Technologies: OraSure develops oral fluid collection devices (Intercept) used in workplace and criminal justice drug testing, representing a modality alternative to MEDTOX's urine-based immunoassays.
  • Confirm Biosciences: Confirm Biosciences offers a portfolio of rapid urine drug test cups and saliva-based oral fluid drug testing kits, overlapping with MEDTOX's product line especially in workplace and at-home testing channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

MEDTOX Diagnostics social profiles

Digital presence

MEDTOX Diagnostics compliance and trust

Trust signal

Compliance3 records

MEDTOX Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MEDTOX Diagnostics leadership team

Management profile

Number of profiles

Profiles4 records

MEDTOX Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MEDTOX Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MEDTOX Diagnostics

What does MEDTOX Diagnostics do?

MEDTOX Diagnostics manufactures and sells FDA 510(k)-cleared rapid drug testing devices, including single-step immunoassay cassettes and cups that deliver qualitative urine drug screening results within minutes. The portfolio includes the MEDTOXScan automated reader system, multi-panel cassettes (PROFILE and VERDICT lines), EZ-SCREEN cups with on-board adulteration strips, and the Labcorp Fentanyl Test, all produced at its Burlington, North Carolina facility under ISO 13485:2016 quality certification.

Is MEDTOX Diagnostics a public or private company?

MEDTOX Diagnostics is a private company. It is classified as corporate owned and is currently operating.

When was MEDTOX Diagnostics founded?

MEDTOX Diagnostics was founded in 1987. It employs 11 to 50 people.

Where is MEDTOX Diagnostics based?

MEDTOX Diagnostics is headquartered in Burlington, United States, in the North America region.

How does MEDTOX Diagnostics make money?

Two revenue lines are on record. Drug Testing Devices and Consumables are the primary driver. The others are MEDTOXScan Reader Hardware and Licensing.

Who are MEDTOX Diagnostics's main competitors?

Direct peers on record are Abbott Toxicology (formerly Alere), Quest Diagnostics, Psychemedics Corporation, Clinical Reference Laboratory and Premier Biotech. Broad incumbents are Roche Diagnostics, Siemens Healthineers and Labcorp. Emerging players are OraSure Technologies and Confirm Biosciences.

Does MEDTOX Diagnostics have an API?

No public API is recorded for MEDTOX Diagnostics.

What industry is MEDTOX Diagnostics in?

MEDTOX Diagnostics's product category is Point-of-Care Drug Testing Devices. Its primary akta.pro industry code is HLAHAOAG, Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels), with a secondary code of HLAGADAC, Release Testing & Batch Certification (QC). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales